Literature DB >> 126800

Dose response in vivo to digoxin in normo-and hyperkalaemia: associated biochemical changes.

R H Goldman, D J Coltart, E Schweizer, G Snidow, D C Harrison.   

Abstract

The effect of digoxin, at two different inotropic levels, was examined in normo- and hyperkalaemic dogs. For similar inotropic responses, normo- and hyperkalaemic dogs had similar levels of (Na+, K+)-ATPase inhibition and microsomal-bound digoxin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 126800     DOI: 10.1093/cvr/9.4.515

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

1.  Reduction of the equilibrium binding of cardiac glycosides and related compounds to Na+,K+-ATPase as a possible mechanism for the potassium-induced reversal of their toxicity.

Authors:  T Akera; K Temma; S A Wiest; T M Brody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

2.  Saturable adenosine 5'-triphosphate-independent binding of [3H]-ouabain to brain and cardiac tissue in vitro.

Authors:  T Akera; T M Brody; S A Wiest
Journal:  Br J Pharmacol       Date:  1979-03       Impact factor: 8.739

3.  Release of adenine nucleotide metabolites by toxic concentrations of cardiac glycosides.

Authors:  W Bernauer
Journal:  Basic Res Cardiol       Date:  1994 Jul-Aug       Impact factor: 17.165

4.  [The problem of the cellular receptor for cardiac glycosides (author's transl)].

Authors:  H H Bodemann
Journal:  Klin Wochenschr       Date:  1981-12-15

5.  Inhibition of the sodium pump in guinea-pig ventricular muscle by dihydro-ouabain: effects of external potassium and sodium.

Authors:  J Daut
Journal:  J Physiol       Date:  1983-06       Impact factor: 5.182

6.  The influence of reduced serum potassium level on the toxicity of some cardenolides in guinea pigs.

Authors:  U Fricke; W Klaus
Journal:  Basic Res Cardiol       Date:  1981 Jan-Feb       Impact factor: 17.165

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.